Trial Profile
ARTSS-IA: A Pilot, Phase IIa, Safety and Feasibility Study of ARgatroban in Combination With Recombinant Tissue Plasminogen Activator Stroke Study - Intra-Arterial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Argatroban (Primary)
- Indications Arterial occlusive disorders; Stroke
- Focus Adverse reactions
- Acronyms ARTSS-IA
- 24 Feb 2017 Status changed from recruiting to completed.
- 24 Feb 2017 Results presented at the 42nd International Stroke Conference
- 18 May 2015 New trial record